Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases

Modern Pathology

Volumn 28, Issue 12, 2015, Pages 1535-1544

  Kakavand, Hojabr ^a,b,c   Vilain, Ricardo E ^a,c   Wilmott, James S ^a,b   Burke, Hazel ^a   Yearley, Jennifer H ^d   Thompson, John F ^a,b   Hersey, Peter ^a,b,e   Long, Georgina V ^a,b   Scolyer, Richard A ^a,b,c  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d MERCK RESEARCH LABORATORIES   (United States)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; LYMPHOCYTE ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CELL INTERACTION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; METASTATIC MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE METASTASIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 84949539261     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.110     Document Type: Article

References (39)

1. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. New Engl J Med 2014; 370: 599-609
2. Balch CM, Gershenwald JE, Soong S-j, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009 27: 6199-6206
3. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126
4. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-Analysis. J Nat Cancer I 2010; 102: 493-501
5. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17
6. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363: 711-723
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011; 364: 2507-2516
9. Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
10. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New Engl J Med 2014; 371: 1877-1888
11. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. New Engl J Med 2015; 372: 30-39
12. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New Engl J Med 2014; 371: 1867-1876
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012; 366: 2443-2454
14. Hamid O, Robert C, Daud A, et al. Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. New Engl J Med 2013; 369: 134-144
15. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887
16. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
17. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034
18. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369
19. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268
20. Tseng S-Y, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-846
21. Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538-5545
22. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297
23. Dong H, Strome SE, Salomao DR, et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800
24. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-1394
25. Kakavand H, Wilmott JS, Menzies AM, et al. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. Clin Cancer Res 2015; 21: 3140-3148
26. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571
27. Morton DL, Thompson JF, Cochran AJ, et al. Sentinelnode biopsy or nodal observation in melanoma. New Engl J Med 2006; 355: 1307-1317
28. Eggermont AM (ed). Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. Proceedings of the ASCO Annual Meeting; 30 May-03 June 2014; Chicago, IL, USA. American Society of Clinical Oncology: Chicago, IL, USA, 2014
29. Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigm Cell Mel Res 2014; 28: 245-253
30. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37-1ra37r
31. Gadiot J, Hooijkaas AI, Kaiser ADM, et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117: 2192-2201
32. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med 2015; 372: 320-330
33. Kefford R (ed). Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Proceedings of the ASCO Annual Meeting; 30 May-03 June 2014; Chicago, IL, USA. American Society of Clinical Oncology: Chicago, IL, USA, 2014
34. Herbst RS (ed). A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Proceedings of the ASCO Annual Meeting; 31 May-04 June 2013; Chicago, IL, USA. American Society of Clinical Oncology: Chicago, IL, USA, 2013
35. Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567
36. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. J Clin Oncol 2012; 30: 2678-2683
37. Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-1310
38. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 43-47
39. Viguier M, Lemaître F, Verola O, et al. Foxp3 expressing CD4+ CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 1444-1453